TipRanks
pc:vader

Vaderis Therapeutics

Vaderis Therapeutics is a clinical-stage biopharmaceutical company developing engasertib, a once-daily oral therapy for hereditary hemorrhagic telangiectasia (HHT). The company is transitioning into pivotal-stage development with initiation of the global Phase 3 HEROIC study evaluating engasertib in patients with moderate-to-severe HHT.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation―
Estimated Valuation―
Total Amount Raised$152M
Total Amount Raised$152M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$152M
Latest Funding Amount$152M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation―
Post-Money Valuation―

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Aug 11, 2026
Series B
$152.00M
―

Investors

Investor Name
Funding Round

Similar Companies

A snapshot of private companies similar to Vaderis Therapeutics, helping you discover and navigate related company profiles.

Related News and Analysis